BLTE
What one share of Belite Bio holds
Pharmaceutical Preparations
We are a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have significant unmet medical need such as (i) Geographic Atrophy (GA), the late atrophic (“dry”) form of age-related macular degeneration (AMD), and (ii) Stargardt disease type 1 (STGD1).
Belite Bio’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Profit | −$2.31 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.10 |
| Cash and investments | $8.97 |
| Book value | $19.59 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$0.65 | — | −$0.51 | — | −$0.80 |
| 2021 | — | −$1.01 | $0.01 | −$0.79 | — | −$1.47 |
| 2022 | — | −$0.63 | $0.02 | −$0.59 | — | $1.67 |
| 2023 | — | −$1.19 | $0.00 | −$1.12 | — | $3.10 |
| 2024 | — | −$1.18 | $0.00 | −$0.96 | — | $4.58 |
| 2025 | — | −$2.31 | $0.00 | −$1.10 | — | $19.59 |